© 2015 Butantan Institute - Reproduction forbidden without prior authorization

6th Global Biodiversity

Heritage Library

mission

To contribute to public health through research, innovation, production and

development of biological products, sharing knowledge with the society

vision

To be a world-class public institution dedicated to research, development,

dissemination, education and the manufacturing of biological products for public

health demands

2.151 direct employees

33% public employees

67% Foundation workers

~100 outsourced employees

Instituto Butantan

Vaccine and Sera Production

Scientific Research & Development

Cultural Center Other areas

Butantan Foundation

organizational structure

Source: Instituto Butantan (Nov 2014)

~750,000 m2 300,000 60% in the heart of visitors/year preserved

the urban area green area

Bu

tan

tan

cam

pu

s

4 museums

biological museum

history museum microbiology museum

Emílio Ribas museum

Bu

tan

tan

cam

pu

s

scie

nti

fic r

esearc

h &

develo

pm

en

t la

bs

• 19 scientific labs

- Scientific Development Division [16 labs]

- Special Lab for Applied Toxinology - LETA [3 labs]

• Center of Biotechnology [8 labs]

• Hospital Vital Brazil [10 beds]

• Central Animal Facility

• 180 PhD researchers

• 500 graduate students

Sources: Instituto Butantan; ISI web of Science Feb2015

number of research articles and citations - 2011-2014

198

207

215

214

3.755 3.945

4.446 4.727

0

500

1.000

1.500

2.000

2.500

3.000

3.500

4.000

4.500

5.000

185

190

195

200

205

210

215

220

2011 2012 2013 2014

artigos publicados* citações totaisarticles citations

scie

nti

fic r

esearc

h &

develo

pm

en

t la

bs

Labs

Arthropods

Bacteriology

Biochemistry

Biotechnology Center

Cell Cycle

Cellular Biology

Ecology and Evolution

Genetic

Herpetology

Immunochemistry

Immunogenetics

Immunopathology

Pain and Signaling

Parasitology

Pathophysiology

Pharmacology

Special Lab of Applied Toxinology

Viral Immunology

Virology

Zoological Collections

4 major areas

animal

biology

vaccinology development

toxinology

ed

uc

ati

on

al p

rog

ram

s

• scientific knowledge courses venomous animals; venomous insects; sera and vaccines; pharmacovigilance; amphibian

biology; introduction to microscopy, etc.

• more than 20 graduate extension courses introduction to immunobiology; analytical tools applied to public health and environmental

management; microbiology practices; introduction to education in museums; etc.

• PAP - Professional Advancement

Program Health sector professional training

• Scientific Initiation scholarships for undergraduate students

participating in Butantan research projects

• MBA in Innovation

Trains professionals for the management

of critical functions of the innovation

process, promoting the creation of

mechanisms to facilitate technology

transfers.

• Inter-institutional Graduate Studies in Biotechnology

[University of São Paulo, Institute for Technological Research - IPT, Instituto Butantan]

• Graduate Studies in Toxinology

approved by CAPES in August 2010, with a grade of 5 (out of 7 points), for Masters and PhDs

an

tive

no

m p

rod

uc

tio

n

horse immunization São Joaquim Farm

50 km from São Paulo

~ 800 horses

22,000 liters of plasma/year

snake facility

~1,000 animals

- Bothrops - 5 species

- Crotalus - 2 subspecies

- Lachesis - 1 species

- Micrurus - 2 species

spider / scorpion facility ~ 15,000 animals

- Loxosceles spider (brown spider)

- Phoneutria spider (banana spider)

- Tityus scorpion (yellow scorpion)

caterpillar lab ~ 600 animals

- Lonomia caterpillar

ve

no

n f

or

an

tive

no

m p

rod

uc

tio

n

ind

us

tria

l c

om

ple

x -

pro

du

cti

on

7 plants

• Anaerobic vaccines - Tetanus and Botulism

• Bacterial Purification Center

• Aerobic Vaccines - Diphtheria and Pertussis

• Hepatitis B

• Influenza

• Rabies

• Sera

1 Formulation and Filling Center

6 multifunctional pilot plants o Dengue

o Rotavirus

o Recombinant BCG

o Monoclonal antibodies

o Influenza - H5N1

o Blood products

po

rtfo

lio

of

se

rum

pro

du

cts

13 immunoglobulins

400,000 vials/year

5 snake antivenoms diphtheria antitoxin

spider antivenom

caterpillar antivenom

tetanus antitoxin

botulism E antitoxin

rabies antiviral

botulism AB antitoxin

scorpion antivenom

po

rtfo

lio

of

va

cc

ine

s

6 vaccines of the national calendar

150 million doses per year

DTP

Diphtheria-Tetanus-Pertussis (celular)

DT

Diphtheria-Tetanus (for children)

dT

Diphtheria-Tetanus

(for adults)

rabies

hepatitis B

Influenza

dis

trib

uti

on

an

d n

um

be

rs

Hepatitis B

- 1st recombinant vaccine produced

in Brazil

- 100% produced by Instituto Butantan

- target audience (2013):150 million people

under the age of 49 years

(75,6% of the population)

- 800.000 carriers in Brazil

HPV

- 685,400 infected people/year

- 95% of the cases of cervical cancer

- second most common cancer in women

Sources: SINAN; website Portal da Saúde - SUS;

Ministry of Health (2013)

PNI – Programa Nacional de Imunizações [National Immunization Program]

free of charge vaccination

5.570 cities - 27 states (all Brazilian states)

7 official vaccine manufacturers

Source: Ministério da Saúde, set 2014

423 m 384 m 1.4 b 845 m USD 757 m 802 m 1.1 b

29%

42% 36%

40% 48%

40% 40%

21%

34% 39%

40%

15% 35% 32% 5%

5% 3%

4%

5%

4% 4%

2%

4%

5%

5%

11%

8% 7%

6%

4% 34%

11% 13% 6%

27%

12%

24%

0%

20%

40%

60%

80%

100%

120%

2008 2009 2010 2011 2012 2013 2014

% o

f a

cq

uir

ed

do

se

s

Opas (17 vaccines)

Tecpar (1 vaccine)

Funed (1 vaccine)

FAP (1 vaccine)

Butantan (6 vaccines)

Bio-Manguinhos /Fiocruz (9 vaccines)

doses 328 m 306 m 452 m 311 m 211 m 230 m 235 m

Ministry of Health acquisitions

Pro

gra

ma

Na

cio

na

l d

e Im

un

iza

çõ

es

- P

NI

po

iso

no

us

an

ima

ls

study of bioactive components of poisonous animals

pharmacological activities

• analgesic

• anti-inflammatory

• anticoagulant

• antitumor

• nervous system related action

• anti-hypertensive

pa

ten

ts

* others include: propolis extract, protein from

Leptospira, spider proteins, recombinant protein

for AIDS diagnosis, etc.

Lopap – 4 patents

Biolab / Fapesp

Amblyomin-X – 2 patents

União Química / Fapesp

Silica (SBA-15) – 1 patent

Cristália / Fapesp

patents quantity vaccine 12

serum 3

immunotherapy 3

haemostasis 2

analgesic 2

peptide 2

tissue regeneration 2

anti cancer 1

antibody 2

others* 11

total 40

Pertussis low – 1 patent

Crotalphine – 2 patents

Biolab / Fapesp

pip

elin

e

nr products description

1 Dengue Vaccine Attenuated tetravalent vaccine (serotypes DEN1, DEN2, DEN3, DEN4) –

Phase 2 of clinical trials

2 Rotavirus Vaccine Attenuated pentavalent vaccine (serotypes G1, G2, G3, G4, G9) –

Phase 2 of clinical trials

3 Pertussis low Vaccine B. pertussis whole cell with lower content of LPS

4 Pneumococcal Vaccine Inactivated non-encapsulated pneumococcal whole cell

5 DTPlow+HepB+Hib Vaccine Pentavalent - Diphtheria, Tetanus, Whooping cough, Hepatitis B and

Haemophilus Influenza type B

6 DTPlow+HepB+Hib+IPV+MenC Vaccine Heptavalent - Diphtheria, Tetanus, Whooping cough, Hepatitis B,

Haemophilus Influenza type B, Polio and Meningococcal type C

7 Hepatitis B + MPLA Vaccine For > 50 years old and immunocompromised persons

8 rBCG + Hep B Vaccine For neonates

9 Onco rBCG Vaccine For bladder cancer treatment

10 Adjuvant BpMPLA BpMPLA derived from LPS of B.pertussis to be combined to different vaccines

11 Bee’s Antivenom Treatment against multiple bee stings

12 Lung surfactant For neonates

13 Sílica (SBA-15) Adjuvant for orally administrated vaccines

14 Amblyomin-X Anticancer medicine, obtained from tick saliva

15 Crotalphine Potent analgesic drug from snake venom. Long-lasting analgesic (2-5 days)

16 Crotamin Cell penetrating peptide - Introduction of genetic materials into the cells, such as

DNA and RNA

17 Lopap Prothrombin Activator, anti-apoptotic activity and other pharmaceutical formulations

18 Monoclonal antibodies Anti-CD3 for transplantion rejection and other monoclonals for other uses

19 Hemoderivatives Production of IgG, factor VIII, IX, Albumin and other products

IIBB will

• be a center dedicated to research, innovation and generation of

innovative enterprises

• be located at a renovated building (35.000 m2)

• promote its own enterprises as well as joint ventures with public and private

institutions (domestic or international), through industrial, commercial and

corporate models suited to each kind of project

Bu

tan

tan

In

sti

tute

fo

r

Inn

ova

tio

n i

n B

iote

ch

no

log

y -

IIB

B

IIBB

conceptual

design

na

tio

na

l a

nd

in

tern

ati

on

al p

art

ne

rsh

ips

Harvard

Board of Directors - Instituto Butantan

Board of Curators - Fundação Butantan André Franco Montoro Filho

Carlos Wendel de Magalhães

Erney F. Plessmann de Camargo

Fernando de Souza Meirelles

Gonzalo Vecina Neto

João Fernando Gomes da Oliveira

Jorge Kalil

Luiz R. Raja Gabaglia Travassos

Luiz Vicente Rizzo

Moisés Goldbaum

Paulo Lee Ho

Yara Cury

Finance Council - Fundação Butantan Carlos Alberto Marsal

Israel Domingos Bacas

Joaquim José C. Engler

Geraldo Alckmin Governor of the State

of São Paulo

David Uip State Secretary of Health

Sergio Swain Muller Science, Technology and

Strategical Health Products

Coordinator

Jorge Kalil Director of Instituto Butantan

President of Fundação Butantan

Marcelo de Franco

Vice-director of Instituto Butantan